Quarterly report pursuant to Section 13 or 15(d)

Description of Business and Summary of Significant Accounting Policies (Details Narrative)

v3.21.1
Description of Business and Summary of Significant Accounting Policies (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Mar. 31, 2021
Jan. 03, 2021
Dec. 21, 2020
Feb. 28, 2021
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Jan. 14, 2021
Dec. 31, 2019
Net loss         $ (2,948,486) $ (1,359,246)      
Net cash used in operating activities         (782,116) (451,145)      
Stockholders'deficit $ (4,035,365)       (4,035,365) (544,309) $ (2,608,246)   $ 278,941
Cash on hand $ 313,525       313,525   $ 6,270    
Subscriptions to purchase, value         $ 1,231,000        
Subscriptions to purchase, share         73,895,644        
Advertising costs         $ 57,959 33,682      
Research and development costs         $ 130,825 $ 77,876      
Options outstanding 1,325,000       1,325,000   4,130,000    
Options exercisable 975,814       975,814        
Debt conversion, description         It should be noted that contractually the limitations on the third-party notes (and the related warrant) limit the number of shares converted to either 4.99% or 9.99% of the then outstanding shares.        
Accounting Standards Update 2020-06 [Member]                  
Decrease to accumulated deficit   $ 2,054,759              
Decrease in addition paid in capital   2,557,812              
Increase in convertible notes payable   $ 503,053              
Revenue Benchmark [Member]                  
Concentration risk percentage         61.00%        
Accounts Receivable [Member]                  
Concentration risk percentage         100.00%        
Customer One [Member] | Revenue Benchmark [Member]                  
Concentration risk percentage         61.00%        
Customer One [Member] | Accounts Receivable [Member]                  
Concentration risk percentage         100.00% 35.00%      
No Customer [Member] | Revenue Benchmark [Member]                  
Concentration risk percentage           10.00%      
No Customer [Member] | Accounts Receivable [Member]                  
Concentration risk percentage         10.00%        
Common Stock [Member] | Convertible Debt [Member]                  
Convertible debt with accrued interest $ 1,499,879       $ 1,499,879        
Number of convertible common shares         97,064,539        
Agent [Member]                  
Prepaid production costs $ 100,000                
Vendors One [Member] | Accounts Payable [Member] | Vendor Concentration Risk [Member]                  
Concentration risk percentage         61.00%        
Vendors Two [Member] | Accounts Payable [Member] | Vendor Concentration Risk [Member]                  
Concentration risk percentage         10.00%        
No Other Vendor [Member] | Accounts Payable [Member] | Vendor Concentration Risk [Member]                  
Concentration risk percentage         10.00%        
Two Vendors [Member] | Accounts Payable [Member] | Vendor Concentration Risk [Member]                  
Concentration risk percentage             63.00%    
Medolife Rx, Inc [Member] | Agent [Member]                  
Prepaid production costs       $ 300,000          
Securities Exchange Agreement [Member] | Medolife Rx, Inc. [Member]                  
Acquisition percentage     51.00%         51.00%  
Share issued in exchange     9,000